stella
beta
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs — Stella
Recruiting
Back to NSCLC (Advanced Non-small Cell Lung Cancer) trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov